Search results
If You Invested $5,000 in Axsome Therapeutics in 2019, This Is How Much You Would Have Today
Motley Fool· 2 years agoAxsome Therapeutics (NASDAQ: AXSM) has been making headlines for two reasons this year. Back in...
Axsome Therapeutics Stock: Bear vs. Bull
Motley Fool· 1 year agoAxsome Therapeutics (NASDAQ: AXSM) was one of last year's hottest stocks. The biotech company had reached an exciting time: the launch of its first...
Axsome (AXSM) Stock Falls Despite Q4 Earnings & Revenue Beat
Zacks via Yahoo Finance· 3 months agoAxsome Therapeutics, Inc. AXSM reported an adjusted loss of 73 cents per share for the fourth...
Axsome's New Drug Is Scoring a Win. Is the Stock a Buy?
Motley Fool· 1 year agoAxsome Therapeutics (NASDAQ: AXSM) stood out last year. The biotech began selling its first two...
Axsome Therapeutics Just Took Its Key Moving Averages — Here's Why
Investor's Business Daily· 2 years agoThe Food and Drug Administration could be nearing a decision on Axsome Therapeutics' depression...
Is a Victory for Its Rivals Bad News for Axsome Therapeutics?
Motley Fool· 1 year agoAXS-05 met its primary and secondary goals in the study, and importantly, looked to be on track to...
Why Is Axsome Therapeutics (AXSM) Stock Up 30% Today?
InvestorPlace via Yahoo Finance· 2 years agoShares of Axsome Therapeutics (NASDAQ:AXSM) are up more than 30% today on news that the biopharmaceutical company has received approval from the U.S. Food and Drug Administration (FDA) for a ...
Missed Out On Axsome Therapeutics? My Best Biotech Stock to Buy and Hold
Motley Fool· 2 years agoAxsome Therapeutics wowed investors when it soared more than 80% this year through August. Investors...
Axsome Therapeutics Expects Up To $11.5 Billion In Peak Sales, Wallops Analysts' Forecasts
Investor's Business Daily· 12 months agoAxsome Therapeutics expects its eight products to generate up to $11.5 billion in peak U.S. sales,...
This Stock Crushed the Market Last Year. Here's Why It Could Do That Again.
Motley Fool· 12 months agoAxsome Therapeutics (NASDAQ: AXSM) started out last year as a small up-and-coming biotech company....
